Given the autoimmunity in the pathogenesis of RP, a number of biologics targeting the cytokine-mediated cascades are being used in patients with RP.[16] Kawai et al have reported satisfactory effects of the anti-interleukin-6 receptor antibody tocilizumab in 2 patients with refractory RP.[17] The positive therapeutic role for IL-6 blockage in these reported cases suggests that the elevated IL-6 levels in the affected sites and IL-6 inhibition may therefore disrupt cellular and humoral immune pathway contributing to PR and its organ involvement. This evidence concerns the gene IL6 and retinitis pigmentosa 1.